| Abstrakt: |
A recent study conducted at the National Cancer Center Hospital East in Japan explored the use of circulating tumor DNA (ctDNA) as a biomarker for detecting residual disease and predicting recurrence in patients with resectable colorectal cancer (CRC). The study analyzed data from 2,695 patients and identified several actionable biomarkers, including RAS/BRAF wild-type, tumor mutational burden (TMB) high, MSI high, BRAF V600E, KRAS G12C, ERBB2 amplification, TP53 Y220C, NTRK1/2/3 fusion, and RET fusion. The presence of ctDNA during the molecular residual disease (MRD) window was associated with worse disease-free survival, and adjuvant chemotherapy was found to provide survival benefits in ctDNA-positive patients with stage II and III disease. The study suggests that ctDNA-based MRD testing could be a valuable tool for prognostication and guiding targeted therapeutic strategies in CRC patients. [Extracted from the article] |
